✦ LIBER ✦

A Pilot Study to Evaluate the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor AZD2171 and Chemotherapy in Locally Advanced and Inflammatory Breast Cancer

✍ Scribed by Neelima Denduluri; Antoinette R. Tan; Janice Walshe; Arlene Berman; Sherry X. Yang; Catherine K. Chow; Sandra M. Swain

Book ID: 115075688
Publisher: CIG Media Group, LP.
Year: 2005
Tongue: English
Weight: 185 KB
Volume: 6
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2005.n.052

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II Safety and Efficacy Study of

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

✍ Pili, Roberto; Qin, Rui; Flynn, P.J.; Picus, Joel; Millward, Michael; Ho, Wing M 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 791 KB

A Multicenter Phase II Trial of ZD6474,

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer

✍ Dickler, M.N. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Antiangiogenic versus cytotoxic therapeu

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine

✍ Guido Bocci; Romano Danesi; Gabriele Marangoni; Anna Fioravanti; Ugo Boggi; Iren 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 578 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Heterogeneity in the angiogenic response

Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast-enhanced MRI

✍ Ka-Loh Li; Lisa J. Wilmes; Roland G. Henry; Maria G. Pallavicini; John W. Park; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

## Abstract ## Purpose To investigate the heterogeneity in the angiogenic response of a human breast cancer xenograft to a novel vascular endothelial growth factor (VEGF)‐receptor tyrosine kinase inhibitor, AG‐013736, using dynamic contrast‐enhanced MR imaging (DCE‐MRI). ## Materials and Methods

93 POSTER Phase I study of daily oral AZ

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; D. Jonker; M. Maclean; J. Wells; S. Mathews; J. Robertson; L. Seymour 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB